Express Scripts says likely to lose top client Anthem
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Cantor Fitzgerald Maintains Neutral Rating and $165 PT on Anthem (ANTM); 'Steps to Improve PBM Leverage Should be Positive'
April 24, 2017 5:26 PM EDTCantor Fitzgerald maintains Neutral rating and $165 price target on Anthem (NYSE: ANTM) as the company's pharmacy benefit manager, Express Scripts (ESRX), announced that it is unlikely that Anthem will renew its contract which expires on December 31, 2019.
Analyst Steven Halper notes the company generated... More
